Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks

Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):1971-5. doi: 10.1007/s00259-015-3186-3.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antigens, Surface
  • Clinical Trials as Topic
  • Docetaxel
  • Europe
  • Glutamate Carboxypeptidase II / antagonists & inhibitors*
  • Humans
  • Ligands
  • Lutetium / adverse effects
  • Lutetium / therapeutic use
  • Male
  • Oligopeptides / adverse effects
  • Oligopeptides / pharmacology
  • Oligopeptides / therapeutic use
  • Prostatic Neoplasms, Castration-Resistant / drug therapy
  • Prostatic Neoplasms, Castration-Resistant / radiotherapy*
  • Radiopharmaceuticals / adverse effects
  • Radiopharmaceuticals / pharmacology
  • Radiopharmaceuticals / therapeutic use*
  • Taxoids / adverse effects
  • Taxoids / therapeutic use

Substances

  • Antigens, Surface
  • Ligands
  • Oligopeptides
  • Radiopharmaceuticals
  • Taxoids
  • Docetaxel
  • Lutetium
  • FOLH1 protein, human
  • Glutamate Carboxypeptidase II